InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Puff Puff Post
MARCH 10, 2020
SOURCE InMed Pharmaceuticals Inc. INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. InMed Pharmaceuticals is exploring the therapeutic potential of CBN in diseases with high unmet medical needs.
Let's personalize your content